Background: While postnatal growth in the first month of life is known to impact retinopathy of prematurity (ROP) risk, the impact of growth later in hospitalization, during critical times of retinal vascularization, remains unknown. The purpose of this study was to assess if postnatal growth and body composition during the second half of neonatal intensive care unit hospitalization were associated with severity of retinopathy of prematurity in very low birth weight preterm infants. Methods: Prospective observational pilot study of 83 infants born <32 weeks gestation and <1500 g, conducted at a Level IV neonatal intensive care unit. Body composition was measured during the second half of hospitalization. Infants were evaluated for retinopathy of prematurity. Logistic regression was performed. Results: Greater gains in fat mass, fat-free mass, and percent body fat from 32 to 37 weeks postmenstrual age and higher % body fat at term postmenstrual age were associated with decreased odds of ≥stage 2 retinopathy of prematurity (p < 0.05). Conclusions: Improved growth later in neonatal intensive care unit hospitalization and increased adiposity at term may reduce odds of severe retinopathy of prematurity.
Maternal obesity is a well-established risk factor for offspring obesity development. The relationship between maternal and offspring obesity is mediated in part by developmental programming of offspring metabolic circuitry, including hypothalamic signaling. Dysregulated hypothalamic inflammation has also been linked to development of obesity. We utilized an established C57Bl/6J mouse model of high-fat, high-sugar diet induced maternal obesity to evaluate the effect of maternal obesity on systemic and hypothalamic TNF-α, IL-6, and IL-1β levels in neonatal and adult offspring. The offspring of dams with obesity demonstrated increased adiposity and decreased activity compared to control offspring. Maternal obesity was associated with decreased plasma TNF-α, IL-6 and IL-1β in adult female offspring and decreased plasma IL-6 in neonatal male offspring. Neonatal female offspring of obese dams had decreased TNF-α gene expression in the hypothalamus compared to control females, while neonatal and adult male offspring of obese dams had decreased IL-6 gene expression in the hypothalamus compared to control males. In summary, our results highlight important sex differences in the inflammatory phenotype of offspring exposed to maternal obesity. Sex-specific immunomodulatory mechanisms should be considered in future efforts to develop therapeutic interventions for obesity prevention and treatment.
3 August 2025 in The Journal of Maternal-Fetal & Neonatal Medicine
Infants exposed to antenatal betamethasone (BMZ) between 34.0 and 36.6 weeks gestational age (GA) have increased risk for neonatal hypoglycemia, a known cause of brain injury. While a shorter latency period between BMZ administration and delivery is associated with an increased risk of neonatal hypoglycemia in late preterm infants, the impact of the BMZ latency period on neonatal hypoglycemia in infants born at term (≥37 weeks) has not been previously characterized. Term infants without additional risk factors such as growth restriction or maternal diabetes are not routinely screened and may be at risk for unrecognized neonatal hypoglycemia. The purpose of this study was to determine whether the latency period from antenatal BMZ administration to delivery impacts the incidence of neonatal hypoglycemia in term infants. This retrospective cohort study analyzed maternal-infant dyads from the University of Minnesota Obstetric Measures database (January 2017-August 2023) who received BMZ during pregnancy and delivered at ≥37 weeks (N = 758). The primary outcome was incidence of early neonatal hypoglycemia, defined as a blood glucose level <40 mg/dL within 48 h of birth, in neonates exposed to BMZ 14 days (remote BMZ; N = 597) prior to delivery. Secondary outcomes included incidence of severe neonatal hypoglycemia (blood glucose level <25 mg/dL within 48 h of birth) and treatment for neonatal hypoglycemia with dextrose gel or IV dextrose. Demographics, pregnancy characteristics, neonatal characteristics, and outcomes were summarized by time from last dose of BMZ to delivery. The most common indication for BMZ was pre-eclampsia/pregnancy-induced hypertension in the recent BMZ group and preterm labor with intact membranes in the remote BMZ group (p < .001). Maternal diabetes status did not differ between groups. The recent BMZ group had lower median GA at birth (37.1 vs. 38.4 weeks, p < .001) and lower birth weight (3.03 vs. 3.29 kg, p < .001). The percentage of neonates classified as small for GA or large for GA was similar between groups. Approximately 30% of the neonates had a documented glucose measurement within 48 h of birth. The incidence of early neonatal hypoglycemia, severe hypoglycemia, and treatment for hypoglycemia with dextrose gel or IV dextrose did not differ between infants exposed to recent BMZ vs. those exposed to remote BMZ. In this cohort of term infants, a shorter latency period between BMZ administration and delivery was not associated with increased incidence or treatment of hypoglycemia. However, the rate of hypoglycemia screening was low in both groups and rates of undiagnosed hypoglycemia in BMZ-exposed term neonates remain unknown. Prospective longitudinal studies aimed at characterizing the risk of hypoglycemia in term infants exposed to BMZ would be beneficial to inform hypoglycemia screening practices in BMZ-exposed neonates.